GleamWall
中文EN

PRCT PROCEPT BioRobotics Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1588978 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY-35.8%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—

Margins

Gross margin64.7%
Operating margin-33.6%
Net margin-32.6%
FCF margin-24.1%
EBITDA margin-31.3%

Returns

ROE-32.4%
ROA-23.3%
ROIC (approx.)-62.4%
Asset turnover0.72x

Leverage & solvency

Liabilities / assets30.6%
Debt / equity0.16x
Current ratio5.89x
Interest coverage-34.73x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$308.05M$224.50M$136.19M$75.01M$34.47M
Cost of revenue$111.83M$87.40M$65.14M$37.93M$18.61M
Gross profit$196.23M$137.10M$71.05M$37.09M$15.87M
R&D expense$71.28M$62.30M$48.45M$28.98M$18.99M
SG&A expense$228.81M$171.41M$131.77M$88.83M$51.04M
Operating income-$103.86M-$96.61M-$109.17M-$80.72M-$54.16M
Interest expense$3.59M$4.18M$4.00M$5.18M$5.81M
Pretax income-$95.38M-$91.05M-$105.82M——
Income tax$190,000$368,000$80,000$0$0
Net income-$95.57M-$91.41M-$105.90M-$87.15M-$59.85M
EBITDA-$97.47M-$91.38M-$105.36M-$77.88M-$50.84M
EPS (basic)-1.72-1.75-2.24-1.96-3.63
EPS (diluted)-1.72-1.75-2.24-1.96-3.63
Weighted avg. shares (diluted)55.54M52.12M47.26M44.40M16.48M
Banking
Provision for credit losses—$840,000$0$0—
Balance sheet
Cash & equivalents$286.50M$336.76M$257.22M$225.67M$305.10M
Receivables$83.53M$83.50M$48.38M$15.27M$4.46M
Inventory$70.69M$56.17M$39.76M$28.54M$13.15M
Current assets$450.38M$481.84M$350.57M$272.63M$326.17M
PP&E, net$30.40M$26.71M$28.75M$8.66M$5.04M
Total assets$508.08M$534.02M$404.72M$309.33M$337.02M
Current liabilities$65.80M$53.13M$45.93M$35.29M$16.24M
Short-term debt————$0
Long-term debt$51.62M$51.47M$51.34M$51.21M$50.00M
Total debt$51.62M$51.47M$51.34M$51.21M$50.00M
Total liabilities$142.21M$131.80M$123.97M$112.26M$69.93M
Shareholders' equity$365.87M$402.22M$280.75M$197.07M$267.09M
Net debt-$234.89M-$285.29M-$205.88M-$174.46M-$255.09M
Shares outstanding56.32M54.72M50.77M44.83M43.68M
Cash flow statement
Operating cash flow-$48.98M-$99.21M-$108.00M-$80.38M-$57.33M
Capital expenditure$9.36M$4.41M$25.21M$2.65M$592,000
Free cash flow-$58.34M-$103.62M-$133.21M-$83.03M-$57.93M
Investing cash flow-$9.36M-$4.41M-$25.21M-$2.65M-$592,000
Financing cash flow$11.19M$180.12M$167.79M$3.61M$262.12M
Depreciation & amortization$6.39M$5.23M$3.81M$2.84M$3.32M
Stock-based compensation$47.60M$31.84M$19.13M$10.34M$3.80M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.